Roche's T-DM1 (Herceptin-plus) shows early benefit in first-line metastatic breast cancer
This article was originally published in Scrip
Executive Summary
Roche's new HER2-targeting product T-DM1 (trastuzumab emtansine) has shown promising results in another Phase II study, indicating that it may prolong progression-free survival with the additional benefit of fewer side-effects than standard therapy when used first line in metastatic breast cancer.